Nanosafety

Nanosafety is a critical facet of ensuring the responsible development and application of nanotechnology-based drugs and products. With the increasing integration of nanomaterials in pharmaceutical formulations, concerns about potential adverse effects on human health and the environment have grown. Rigorous safety assessments are essential to address these concerns, encompassing aspects such as toxicity, biodistribution, and biocompatibility of nanomaterials. Comprehensive studies are conducted to understand the interactions between nanoparticles and biological systems, evaluating their potential to induce cellular damage or trigger immune responses.

Regulatory bodies and industry stakeholders collaborate to establish guidelines that govern the safe use of nanomaterials in pharmaceuticals, aiming to mitigate risks and enhance patient safety. Moreover, ongoing research endeavors focus on developing innovative nanosafety assessment methods and predictive models to streamline the evaluation process. As the pharmaceutical landscape continues to advance with nanotechnology, prioritizing nanosafety remains paramount to harness the full therapeutic potential of these novel formulations while safeguarding public health.

Committee Members
Speaker at Drug Delivery Events - Vladlen Slepak

Vladlen Slepak

University of Miami Miller School of Medicine, United States
Speaker at Drug Delivery Events - Yong Xiao Wang

Yong Xiao Wang

Albany Medical College, United States
Speaker at Pharmaceutical Conference - Consolato M Sergi

Consolato M Sergi

Universities of Alberta and Ottawa, Canada
Speaker at Drug Delivery Events - Huiqin Yang

Huiqin Yang

ICON Clinical Research Ltd, United Kingdom

Submit your abstract Today

Youtube
Watsapp